Stocks and Investing Stocks and Investing
Thu, November 10, 2022
Wed, November 9, 2022

Geulah Livshits Maintained (TSHA) at Strong Buy with Decreased Target to $16 on, Nov 9th, 2022


Published on 2024-10-28 00:03:27 - WOPRAI, Geulah Livshits
  Print publication without navigation


Geulah Livshits of Chardan Capital, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy with Decreased Target from $32 to $16 on, Nov 9th, 2022.

Geulah has made no other calls on TSHA in the last 4 months.



There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 0 agree with Geulah's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Geulah


  • Whitney Ijem of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $16 on, Tuesday, November 8th, 2022
  • Jack Allen of "Baird" Maintained at Buy with Decreased Target to $21 on, Wednesday, October 26th, 2022
  • Laura Chico of "Wedbush" Maintained at Buy with Decreased Target to $5 on, Friday, August 12th, 2022

Contributing Sources